The Valley Desk

ArticleFuture oncology (London, England)Published

Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University. Affiliation source

Publication record

Type
Article
Venue
Future oncology (London, England)
Published
Subject terms
Humans; Glioblastoma; Brain Neoplasms; Oligonucleotides, Antisense; Antineoplastic Agents, Alkylating; Drug Combinations; Disease-Free Survival; Immunotherapy; Randomized Controlled Trials as Topic; Temozolomide; Radiation; Antisense
PubMed ID
38060340
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal